ANTI-DEPRESSANT MAY HELP TREAT COVID-19 BY JIM DRYDEN
In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Medicine have found that the anti-depressant drug fluvoxamine seems to prevent some of the most serious complications of the illness, and makes hospitalization and the need for supplemental oxygen less likely.
The study involved 152 people infected with SARS-CoV-2, the virus that causes COVID-19. Researchers compared the outcomes of those treated with fluvoxamine to the outcomes of those given an inactive placebo. After 15 days, none of the 80 people who had received the drug experienced serious clinical deterioration. Meanwhile, six of the 72 given placebo (8.3%) became seriously ill, with four requiring hospitalization.
FLUVOXAMINE—SHOWN IN THE MOLECULAR FORMULA ABOVE—IS OFTEN USED TO TREAT OBSESSIVE-COMPULSIVE DISORDER AND DEPRESSION.
Image courtesy of Shutterstock
“The patients who took fluvoxamine did not develop serious breathing difficulties or require hospitalization for problems with lung function,” says the study’s first author, Eric Lenze, MD, Washington University psychiatrist at Barnes-Jewish Hospital. “Most investigational treatments for COVID-19 have been aimed at the very sickest patients, but it’s also important to find therapies that prevent patients from getting sick enough to require supplemental oxygen or to have to go to the hospital. Our study suggests fluvoxamine may help fill that niche.”
Fluvoxamine is used commonly to treat obsessive-compulsive disorder (OCD), social anxiety disorder and depression. It is in a class of drugs known as selective serotonin-reuptake inhibitors (SSRIs), but unlike other SSRIs, fluvoxamine interacts strongly with a protein called the sigma-1 receptor. That receptor also helps regulate the body’s inflammatory response.
“There are several ways this drug might work to help COVID-19 patients, but we think it most likely may be interacting with the sigma-1 receptor to reduce the production of inflammatory molecules,” says Angela Reiersen, MD, Washington University psychiatrist at Barnes-Jewish Hospital and the study’s senior author. “Past research has demonstrated that fluvoxamine can reduce inflammation in animal models of sepsis, and it may be doing something similar in our patients.” READ MORE